Cargando…

Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma

The HIV-protease inhibitor nelfinavir has shown broad anticancer activity in various preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI)–refractory multiple myeloma, nelfinavir-based therapy resulted in 65% partial response or better, suggesting that this may be a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Besse, Lenka, Besse, Andrej, Stolze, Sara C., Sobh, Amin, Zaal, Esther A., van der Ham, Alwin J., Ruiz, Mario, Phuyal, Santosh, Büchler, Lorina, Sathianathan, Marc, Florea, Bogdan I., Borén, Jan, Ståhlman, Marcus, Huber, Julia, Bolomsky, Arnold, Ludwig, Heinz, Hannich, J. Thomas, Loguinov, Alex, Everts, Bart, Berkers, Celia R., Pilon, Marc, Farhan, Hesso, Vulpe, Christopher D., Overkleeft, Herman S., Driessen, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Translational Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7611616/ https://www.ncbi.nlm.nih.gov/pubmed/34158378 http://dx.doi.org/10.1158/0008-5472.CAN-20-3323

Ejemplares similares

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
por: Besse, A, et al.
Publicado: (2018)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
por: Soriano, G P, et al.
Publicado: (2016)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors
por: Besse, Andrej, et al.
Publicado: (2022)

High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
por: Besse, Lenka, et al.
Publicado: (2021)

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Schwestermann, Jonas, et al.
Publicado: (2022)

Membrane Fluidity Is Regulated Cell Nonautonomously by Caenorhabditis elegans PAQR-2 and Its Mammalian Homolog AdipoR2
por: Bodhicharla, Rakesh, et al.
Publicado: (2018)

AdipoR1 and AdipoR2 maintain membrane fluidity in most human cell types and independently of adiponectin
por: Ruiz, Mario, et al.
Publicado: (2019)

Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer
por: Guan, Min, et al.
Publicado: (2015)

Multifaceted Rho GTPase Signaling at the Endomembranes
por: Phuyal, Santosh, et al.
Publicado: (2019)

Want to leave the ER? We offer vesicles, tubules, and tunnels
por: Phuyal, Santosh, et al.
Publicado: (2021)

Induction of Suicidal Erythrocyte Death by Nelfinavir
por: Bissinger, Rosi, et al.
Publicado: (2015)

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
por: Besse, L, et al.
Publicado: (2017)

Evolutionarily conserved long-chain Acyl-CoA synthetases regulate membrane composition and fluidity
por: Ruiz, Mario, et al.
Publicado: (2019)

AdipoR2 recruits protein interactors to promote fatty acid elongation and membrane fluidity
por: Ruiz, Mario, et al.
Publicado: (2023)

Nelfinavir: An Old Ally in the COVID-19 Fight?
por: Gidari, Anna, et al.
Publicado: (2022)

Précis de philosophie / Anne Boissière
por: Besse, Jean-Marc

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

Fluidity of the body
por: Kothari, Manu, et al.
Publicado: (2014)

Finding Fluidity
por: Kenchington-Evans, Lily
Publicado: (2022)

Membrane fluidity is regulated by the C. elegans transmembrane protein FLD-1 and its human homologs TLCD1/2
por: Ruiz, Mario, et al.
Publicado: (2018)

Exploratory differential gene expression analysis in microarray experiments with no or limited replication
por: Loguinov, Alexander V, et al.
Publicado: (2004)

Bilateral uveitis associated with concurrent administration of rifabutin and nelfinavir
por: Cheng, Wen-Hsin, et al.
Publicado: (2015)

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir
por: Subeha, Mahbuba R., et al.
Publicado: (2020)

Flotillin-mediated membrane fluidity controls peptidoglycan synthesis and MreB movement
por: Zielińska, Aleksandra, et al.
Publicado: (2020)

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
por: Zhou, X., et al.
Publicado: (2023)

Rho Signaling Participates in Membrane Fluidity Homeostasis
por: Lockshon, Daniel, et al.
Publicado: (2012)

Fluidity onset in graphene
por: Bandurin, Denis A., et al.
Publicado: (2018)

Systemic Transitional Fluidity
por: Ali, S. Mahmud
Publicado: (2015)

Disrupting enzyme fluidity
por: Anand, Ganesh Srinivasan
Publicado: (2021)

The Influence of Metabolism on Drug Response in Cancer
por: Zaal, Esther A., et al.
Publicado: (2018)

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells
por: Brüning, Ansgar, et al.
Publicado: (2010)

New Insights into the In Silico Prediction of HIV Protease Resistance to Nelfinavir
por: Antunes, Dinler A., et al.
Publicado: (2014)

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children
por: Resino, Salvador, et al.
Publicado: (2006)

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells
por: Kraus, Johannes, et al.
Publicado: (2015)

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023)

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors
por: Blumenthal, Gideon M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mai2li5f74pp1n5gu2pitmp2p1